Cargando…

Hepatitis C microelimination among people living with HIV in Taiwan

To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017. Evaluating the progress of HCV microelimination among people living with HIV (PLWH) is a critical step to identify the barrier...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guan-Jhou, Ho, Shu-Yuan, Su, Li-Hsin, Chang, Sui-Yuan, Hsieh, Szu-Min, Sheng, Wang-Huei, Liu, Wang-Da, Huang, Yu-Shan, Lin, Kuan-Yin, Chen, Yi-Ting, Su, Yi-Ching, Liu, Wen-Chun, Sun, Hsin-Yun, Hung, Chien-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225706/
https://www.ncbi.nlm.nih.gov/pubmed/35608049
http://dx.doi.org/10.1080/22221751.2022.2081620
_version_ 1784733678045233152
author Chen, Guan-Jhou
Ho, Shu-Yuan
Su, Li-Hsin
Chang, Sui-Yuan
Hsieh, Szu-Min
Sheng, Wang-Huei
Liu, Wang-Da
Huang, Yu-Shan
Lin, Kuan-Yin
Chen, Yi-Ting
Su, Yi-Ching
Liu, Wen-Chun
Sun, Hsin-Yun
Hung, Chien-Ching
author_facet Chen, Guan-Jhou
Ho, Shu-Yuan
Su, Li-Hsin
Chang, Sui-Yuan
Hsieh, Szu-Min
Sheng, Wang-Huei
Liu, Wang-Da
Huang, Yu-Shan
Lin, Kuan-Yin
Chen, Yi-Ting
Su, Yi-Ching
Liu, Wen-Chun
Sun, Hsin-Yun
Hung, Chien-Ching
author_sort Chen, Guan-Jhou
collection PubMed
description To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017. Evaluating the progress of HCV microelimination among people living with HIV (PLWH) is a critical step to identify the barriers to HCV elimination. PLWH seeking care at a major hospital designated for HIV care in Taiwan between January 2011 and December 2021 were retrospectively included. For PLWH with HCV-seropositive or HCV seroconversion during the study period, serial HCV RNA testing was performed using archived samples to confirm the presence of HCV viremia and estimate the prevalence and incidence of HCV viremia. Overall, 4199 PLWH contributed to a total of 27,258.75 person-years of follow-up (PYFU). With the reimbursement of DAAs and improvement of access to treatments, the prevalence of HCV viremia has declined from its peak of 6.21% (95% CI, 5.39–7.12%) in 2018 to 2.09% (95% CI, 1.60–2.77%) in 2021 (decline by 66.4% [95% CI, 55.4–74.7%]); the incidence has declined from 25.94 per 1000 PYFU (95% CI, 20.44–32.47) in 2019 to 12.15% per 1000 PYFU (95% CI, 8.14–17.44) (decline by 53.2% [95% CI, 27.3–70.6%]). However, the proportion of HCV reinfections continued to increase and accounted for 82.8% of incident HCV infections in 2021. We observed significant declines of HCV viremia among PLWH with the expansion of the DAA treatment programme in Taiwan. Further improvement of the access to DAA retreatments is warranted to achieve the goal of HCV microelimination.
format Online
Article
Text
id pubmed-9225706
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-92257062022-06-24 Hepatitis C microelimination among people living with HIV in Taiwan Chen, Guan-Jhou Ho, Shu-Yuan Su, Li-Hsin Chang, Sui-Yuan Hsieh, Szu-Min Sheng, Wang-Huei Liu, Wang-Da Huang, Yu-Shan Lin, Kuan-Yin Chen, Yi-Ting Su, Yi-Ching Liu, Wen-Chun Sun, Hsin-Yun Hung, Chien-Ching Emerg Microbes Infect Hepatitis To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017. Evaluating the progress of HCV microelimination among people living with HIV (PLWH) is a critical step to identify the barriers to HCV elimination. PLWH seeking care at a major hospital designated for HIV care in Taiwan between January 2011 and December 2021 were retrospectively included. For PLWH with HCV-seropositive or HCV seroconversion during the study period, serial HCV RNA testing was performed using archived samples to confirm the presence of HCV viremia and estimate the prevalence and incidence of HCV viremia. Overall, 4199 PLWH contributed to a total of 27,258.75 person-years of follow-up (PYFU). With the reimbursement of DAAs and improvement of access to treatments, the prevalence of HCV viremia has declined from its peak of 6.21% (95% CI, 5.39–7.12%) in 2018 to 2.09% (95% CI, 1.60–2.77%) in 2021 (decline by 66.4% [95% CI, 55.4–74.7%]); the incidence has declined from 25.94 per 1000 PYFU (95% CI, 20.44–32.47) in 2019 to 12.15% per 1000 PYFU (95% CI, 8.14–17.44) (decline by 53.2% [95% CI, 27.3–70.6%]). However, the proportion of HCV reinfections continued to increase and accounted for 82.8% of incident HCV infections in 2021. We observed significant declines of HCV viremia among PLWH with the expansion of the DAA treatment programme in Taiwan. Further improvement of the access to DAA retreatments is warranted to achieve the goal of HCV microelimination. Taylor & Francis 2022-06-20 /pmc/articles/PMC9225706/ /pubmed/35608049 http://dx.doi.org/10.1080/22221751.2022.2081620 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hepatitis
Chen, Guan-Jhou
Ho, Shu-Yuan
Su, Li-Hsin
Chang, Sui-Yuan
Hsieh, Szu-Min
Sheng, Wang-Huei
Liu, Wang-Da
Huang, Yu-Shan
Lin, Kuan-Yin
Chen, Yi-Ting
Su, Yi-Ching
Liu, Wen-Chun
Sun, Hsin-Yun
Hung, Chien-Ching
Hepatitis C microelimination among people living with HIV in Taiwan
title Hepatitis C microelimination among people living with HIV in Taiwan
title_full Hepatitis C microelimination among people living with HIV in Taiwan
title_fullStr Hepatitis C microelimination among people living with HIV in Taiwan
title_full_unstemmed Hepatitis C microelimination among people living with HIV in Taiwan
title_short Hepatitis C microelimination among people living with HIV in Taiwan
title_sort hepatitis c microelimination among people living with hiv in taiwan
topic Hepatitis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225706/
https://www.ncbi.nlm.nih.gov/pubmed/35608049
http://dx.doi.org/10.1080/22221751.2022.2081620
work_keys_str_mv AT chenguanjhou hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT hoshuyuan hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT sulihsin hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT changsuiyuan hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT hsiehszumin hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT shengwanghuei hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT liuwangda hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT huangyushan hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT linkuanyin hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT chenyiting hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT suyiching hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT liuwenchun hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT sunhsinyun hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan
AT hungchienching hepatitiscmicroeliminationamongpeoplelivingwithhivintaiwan